Market Research Logo

The U.S. Market for OTC Gastrointestinal Products


Attention: There is an updated edition available for this report.

The US Market for OTC Gastrointestinal Products is a comprehensive analysis of the impact OTC drugs have made to the gastrointestinal market. This study provides a detailed market size analysis for the years 1996 - 2000 and market forecasts to the year 2006. Within the OTC Gastrointestinal Product Market three market segments are covered, including: Antacids, H2 Receptor Antagonists, and Other Gastrointestinal Products. A thorough description of upper gastrointestinal conditions and diseases, treatments, and preventive care are included in this study. Trends covered in the report include dual regulatory status, consumer interests in self-medication, and impact of direct-to-consumer advertising. The US Market for OTC Gastrointestinal Products will provide the reader with a comprehensive analysis of gastrointestinal products currently marketed products potentially entering the market. The study focuses on the direction this market is taking and the contributing factors for continued growth. Detailed profiles of major competitors are provided.


Scope and Methodology

The U.S. market for OTC Gastrointestinal Products study focuses on three general product categories, which include:

  • Antacids
  • H2 Receptor Antagonists, and
  • Other Products

The report describes the product categories in detail and the major market factors in each category. The report describes the industry, its relationship to various healthcare delivery channels, and trends for the future. The geographic scope of the report is the United States.

The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 50 key industry officials, trade association spokespersons, consultants, health care providers, and government personnel were complied to form the primary basis of information - specifically revenue and market share data - presented in this report.

All market data pertains to the US market at the manufacturers’ level. The base year for data was 2000. Historical data are provided for 1996 through 1999, with forecast data provided for 2001 through 2006. Compound annual growth rates (CAGRs) are provided for the 1996-1999, 2000-2006, and 1996-2006 periods for each industry segment covered.

Press Release: The U.S. Market for OTC Gastrointestinal Products


Immediate Release
Contact:
Kim Bolus
212.807.2655
kbolus@marketresearch.com

“The U.S. Market for OTC Gastrointestinal Products to Reach Nearly $4 Billion by 2006”
New York, May 16, 2001 /PRNewswire -- The market for OTC gastrointestinal products is projected to grow to $3.9 billion by 2006, with H2-receptor antagonists leading the way, according to a study released today by Kalorama Information, a division of MarketResearch.com.

The study, The U.S. Market for Gastrointestinal Products, reveals how H2-receptor antagonists, such as Tagamet HB, Zantac 75, and Pepcid AC, which began over the-counter sales in 1995, drove growth in the segment over the past 6 years, while steadily encroaching on the market share of traditional antacid products, such as Tums and Rolaids. The H2-receptor antagonists are expected to represent nearly half of the entire OTC gastrointestinal market by 2006.

“In addition to the introduction of the H2-receptor antagonists, an aging population, an ever increasing interest in self care, cost-saving pressures in the healthcare system, and a significant amount of direct consumer advertising have fueled the expansion of the market,” notes Steven Heffner, an editor at Kalorama Information. “And there are many more issues for the industry to confront in the next few years, from changes in the distribution system to generic activity and the big one—the potential arrival of PPIs on drugstore shelves.” PPIs, or proton-pump inhibitors, are yet another therapeutic class of prescription drugs that may gain OTC status in the next few years.

A detailed study of three product categories currently on the OTC Gastrointestinal Market—antacids, H2 receptor antagonists, and other products—the report combines extensive primary research and exhaustive secondary research to provide a comprehensive picture of a changing industry. The report thoroughly analyzes the trends and challenges in the segment provides and market size, growth, and share through 2006.

About MarketResearch.com

Kalorma Information (KLI), a division of MarketResearch.com, reports supply the latest in pharmaceutical research, exploring treatments and technology, legislation, regulation and ideological trends.

About MarketResearch.com

MarketResearch.com is the leading provider of global market intelligence products and services. With over 40,000 research publications from more than 350 top consulting and advisory firms, we offer instant online access to the world’s most extensive database of expert insights on global industries, companies, products and trends. Updated daily. For more information, contact Kim Bolus at 212.807.2655 or kbolus@marketresearch.com, or visit www.MarketResearch.com.

The U.S. Market for Gastrointestinal Products Expected to Reach $4 Billion by the Year 2006

New! The U.S. Market for OTC Gastrointestinal Products report, published by Kalorma Information is now available through MarketResearch.com. The market for over-the-counter gastrointestinal products reached $2.6 billion in manufacturer’s revenue’s in 2000 and the market is expected to reach over $4 billion by 2006.

This report is a comprehensive analysis of the impact OTC drugs had on the gastrointestinal market. The study provides a detailed market size analysis for the years 1996 -2000 and projected market forecasts to the year 2006. This study focuses on the U.S. market in three general categories:

  • Antacids
  • H2 Receptor Antagonists
  • Other Products which include: Alka-Seltzer, Gas-X, Imodium-AD, Pepto-Bismol, and others

Growth in the OTC market for gastrointestinal products has been to some extent, and will continue to be, fueled by several driving factors such as; prescription to over the counter switches of H2 receptor antagonists, a continued aging of the population, an ever increasing interest in self care, the desire of both patients and third party payers for total cost saving in the healthcare system, and a significant amount of direct consumer advertising.

In addition those factors contributing to growth in the market, there are several other issues and trends currently affecting the OTC gastrointestinal market which are detailed in the report, including:

  • Distribution
  • Dual regulatory status
  • Generic activity and impact
  • Legislative and regulatory issues
  • Over the counter labeling issues

As well as many other factors that will be thoroughly examined in this report. This in-depth report includes both secondary and primary research. Primary research was compiled with person to person and telephone interviews with over 50 key industry officials, trade association spokespersons, consultants, healthcare providers, and government personnel to form information specifically for revenue and market share data.

Kalorama Information reports supply the latest in pharmaceutical research, exploring treatments and technology, legislation, regulation and ideological trends.

The U.S. Market for OTC Gastrointestinal Products report is available through MarketResearch.com, the leading provider of global market intelligence products and services. With MarketResearch.com, you can purchase The U.S. Market for OTC Gastrointestinal Products report as a complete study, or buy discrete segments using the options below:

  • MarketLooks - concise, graphic-rich summaries of full-length market research reports available for online delivery. These PowerPoint slides provide industry high points in a presentation-ready format.
  • Buy By the Slice - a cost-effective option that enables you to select and purchase exactly what you value most.

Issues Addressed:

  • Current and project market shares from 1996 through 2006
  • Factors affecting market growth
  • OTC labeling
  • Legislative issues
  • Consumer savings
  • Consumer issues
  • Direct to consumer advertising
  • Distribution
  • Dual regulatory status
  • Generic activity and impact
  • Reimbursement issues
  • Other

Companies/Sites Discussed:

  • 3M Company
  • Bayer Corporation
  • GlaxoSmithKline Consumer Healthcare
  • Johnson & Johnson
  • McNeil Consumer Healthcare
  • Mereck & Company, Inc.
  • Novartis Pharmaceuticals Corporation
  • Perrigo
  • Proctor & Gamble Company
  • Warner-Lambert Consumer Group/Pfizer
  • Waston Pharmaceticals, Inc.
  • Whitehall-Robins Healthcare, Inc.
  • Zenith Goldline Pharmaceuticals

Categories Covered:

  • Antacids
  • H2 Receptor Antagonists
  • Other Products which include: Alka-Seltzer, Gas-X, Imodium-AD, Pepto-Bismol, and others

Tables and Graphs:

  • 42 tables
  • 31 figures

Executive Summary


    Introduction
    Scope and Methodology
    Size and Growth of the Market
    Issues and Trends Affecting the OTC Market
    Leading Competitors

Introduction


    History and Growth of the OTC Market
    Industry Structure
    Food and Drug Administration
    Rx-to-OTC Switches
    Generics
    The Consumer
    Overview of the Upper Gastrointestinal System
    Description of Upper Gastrointestinal Diseases and Conditions
    Gastritis
    GERD (Gastro Esophageal Reflux Disease)
    Heartburn and Indigestion
    Peptic Ulcer Disease
    Prevalence, Incidence
    Risk Factors
    Cost

Antacids


    Overview
    Description of Products
    Aluminum Compounds
    Calcium Carbonates
    Magnesium Compounds
    Combination Preparations
    Rx-to-OTC Switches
    Generic Participation
    Market Size and Growth
    Competitive Analysis

H2 Receptor Antagonists


    Overview
    Description of Products
    Rx-to-Otc Switches
    Generic Participation
    Market Size and Growth
    Competitive Analysis

Other OTC Gastrointestinal Products


    Overview
    Description of Products
    Rx-to-OTC Switches
    Potential Rx-to-OTC Switches
    Generic Participation
    Market Size and Growth
    Potential Market
    Competitive Analysis

Issues And Trends Affecting The OTC Gastrointestinal Product Market


    Introduction
    Consumer Issues
    Education and Self-Medication
    Prescription vs. Over-the-Counter Cost
    Direct-to-Consumer Advertising
    Impact.
    Cost
    Distribution
    Dual Regulatory Status
    Generic Activity and Impact
    Insurance and Reimbursement Issues
    Legislative and Regulatory Issues
    Rx-to-OTC Switch Products
    OTC Labeling Issues
    Line Extensions
    International OTC Trends

Total Market Size And Forecast


    Overview
    Total market Size and Forecast
    Potential Products and Market Forecast
    Competitor Analysis
    Market Analysis

Company Profiles


    3M Company
    Bayer Corporation
    GlaxoSmithKline Consumer Healthcare
    Johnson & Johnson
    McNeil Consumer Healthcare
    Merck & Company, Inc
    Novartis Pharmaceuticals Corporation
    Perrigo Company
    Procter & Gamble Company
    Warner-Lambert Consumer Group/Pfizer
    Watson Pharmaceuticals, Inc.
    Whitehall-Robins Healthcare, Inc.
    Zenith Goldline Pharmaceuticals, Inc.
    Competitive Summary

Company Names And Addresses

List of Exhibits

Chapter One: Executive Summary


    Table 1-1: The U.S. Market for OTC Gastrointestinal Products, by Type, 1996, 2000, and 2006
    Table 1-2: The U.S. Market for OTC Gastrointestinal Products, by Type and Percent Distribution, 1996, 2000, and 2006
    Figure 1-1: The U.S. Market for OTC Gastrointestinal Products, by Type and Revenues, 1996, 2000, and 2006
    Figure 1-2: The U.S. Market for OTC Gastrointestinal Products, by Type and Percent Distribution, 2000
    Table 1-3: Leading Suppliers’ Shares of the U.S. Market for OTC Gastrointestinal Products, 2000
    Figure 1-3: Leading Suppliers’ Shares of the U.S. Market for OTC Gastrointestinal Products, 2000

Chapter Two: Introduction


    Table 2-1: Gastrointestinal Rx-to-OTC Switches by Supplier and Year, 1988-2000
    Table 2-2: Average U.S. Prescription Drug Expenditures per Capita, 1990-2000
    Figure 2-1: Average U.S. Prescription Drug Expenditures per Capita, 1990-2000
    Table 2-3: U.S. Population by Age and Sex, 1996-2006
    Figure 2-2: U.S. Population by Sex, 1996-2006
    Figure 2-3: U.S. Population by Age, 1996-2006
    Table 2-4: U.S. Life Expectancy by Sex, 1996-1999
    Figure 2-4: U.S. Life Expectancy by Sex, 1996-1999
    Table 2-5: U.S. Incidence of GERD Symptoms, 2000
    Figure 2-5: U.S. Incidence of GERD Symptoms, 2000
    Table 2-6: U.S. Incidence of Heartburn and Indigestion Symptoms, 2000
    Figure 2-6: U.S. Incidence of Heartburn and Indigestion Symptoms, 2000
    Table 2-7: U.S. Incidence of Heartburn and Indigestion in Pregnant Women, 2000
    Figure 2-7: U.S. Incidence of Heartburn in Pregnant Women, 2000
    Table 2-8: U.S. Incidence of Peptic Ulcer Disease, 2000
    Figure 2-8: U.S. Incidence of Peptic Ulcer Disease, 2000
    Table 2-9: Common Over-the-Counter Treatments for Ulcer Healing, by Dose and Duration
    Table 2-10: U.S. Annual Health Care Costs of Ulcers, 2000
    Table 2-11: U.S. Average Cost of Treating Ulcers by Treatment Type, 2000

Chapter Three: Antacids


    Table 3-1: Commonly Used Brand Name Aluminum Antacids by Active Ingredient and Manufacturer
    Table 3-2: Commonly Used Brand Name Calcium Antacids by Active Ingredient and Manufacturer
    Table 3-3: Commonly Used Brand Name Magnesium Antacids by Active Ingredient and Manufacturer
    Table 3-4: Commonly Used Brand Name Combination Antacids by Active Ingredient and Manufacturer
    Table 3-5: Generic Antacids by Manufacturer
    Table 3-6: The U.S. Market for OTC Antacids, 1996-2006
    Figure 3-1: The U.S. Market for OTC Antacids, 1996-2006
    Table 3-7: The U.S. Market for OTC Antacids by Percent and Type, 1996-2006
    Figure 3-2: The U.S. Market for OTC Antacids by Type and Revenues, 1996-2006
    Figure 3-3: The U.S. Market for OTC Antacids by Percent and Type 2000
    Table 3-8: U.S. Sales of Leading OTC Antacids, by Product and Supplier, 2000
    Figure 3-4: U.S. Sales of Leading OTC Antacids, by Product and Supplier, 2000
    Table 3-9: Leading Suppliers’ Shares of the U.S. Market for OTC Antacids, 2000
    Figure 3-5: Leading Suppliers’ Shares of the U.S. Market for OTC Antacids, 2000

Chapter Four: H2 Receptor Antagonists


    Table 4-1: Brand Name H2 Receptor Antagonists by Active Ingredient and Manufacturer
    Table 4-2: Generic H2 Receptor Antagonists by Manufacturer
    Table 4-3: The U.S. Market for OTC H2 Receptor Antagonists, 1996-2006.
    Figure 4-1: The U.S. Market for OTC H2 Receptor Antagonists, 1996-2006
    Table 4-4: The U.S. Market for OTC H2 Receptor Antagonists by Percent and Type, 1996-2006
    Figure 4-2: The U.S. Market for OTC H2 Receptor Antagonists by Type and Revenues, 1996-2006
    Figure 4-3: The U.S. Market for OTC H2 Receptor Antagonists by Percent and Type, 2000
    Table 4-5: U.S. Sales of Leading OTC H2 Receptor Antagonists, by Product and Supplier, 2000
    Figure 4-4: U.S. Sales of Leading OTC H2 Receptor Antagonists, by Product and Supplier, 2000
    Table 4-6: Leading Suppliers’ Shares of the U.S. Market for OTC H2 Receptor Antagonists, 2000
    Figure 4-5: Leading Suppliers’ Shares of the U.S. Market for OTC H2 Receptor Antagonists, 2000

Chapter Five: OTC Other Gastrointestinal Products


    Table 5-1: Brand Name OTC Other Gastrointestinal Products by Active Ingredient and Manufacturer
    Table 5-2: Generic OTC Other Gastrointestinal Products by Manufacturer
    Table 5-3: The U.S. Market for OTC Other Gastrointestinal Products, 1996-2006
    Figure 5-1: The U.S. Market for OTC Other Gastrointestinal Products, 1996-2006
    Table 5-4: The U.S. Potential Market for Other Gastrointestinal Products Based on Projected Switches, 2003-2006
    Figure 5-2: The U.S. Potential Market for Other Gastrointestinal Products Based on Projected Switches, 2003-2006
    Table 5-5: U.S. Sales of Leading OTC Other Gastrointestinal Products, by Product and Supplier, 2000
    Figure 5-3: U.S. Sales of Leading OTC Other Gastrointestinal Products, by Product and Supplier, 2000
    Table 5-6: Leading Suppliers’ Shares of the U.S. Market for OTC Other Gastrointestinal Products, 2000
    Figure 5-4: Leading Suppliers’ Shares of the U.S. Market for OTC Other Gastrointestinal Products, 2000

Chapter Six: Issues And Trends Affecting The OTC Gastrointestinal Product Market


    Table 6-1: Cost of OTC Direct-to-Consumer Advertising of Leading OTC Gastrointestinal Pharmaceuticals, 1995 and 1998
    Figure 6-1: Cost of OTC Direct-to-Consumer Advertising of Leading OTC Gastrointestinal Pharmaceuticals, 1995 and 1998
    Table 6-2: National Distribution of OTC Pharmaceuticals, by Selected Retail Stores and Wholesalers

Chapter Seven: Total Market Size And Forecast


    Table 7-1: The U.S. Market for OTC Gastrointestinal Products, by Type, 1996-2006
    Table 7-2: The U.S. Market for OTC Gastrointestinal Products, by Percent and Type, 1996-2006
    Figure 7-1: The U.S. Market for OTC Gastrointestinal Products, by Type and Revenues, 1996-2006
    Figure 7-2: The U.S. Market for OTC Gastrointestinal Products, by Percent and Type, 2000
    Table 7-3: The U.S. Potential Market for Gastrointestinal Products Based on Projected Switches, 2000-2006
    Figure 7-4: The U.S. Potential Market for Gastrointestinal Products Based on Projected Switches, 2003-2006
    Table 7-4: Top Five OTC Gastrointestinal Products, by Product Sales, 2000
    Figure 7-4: Top Five OTC Gastrointestinal Products, by Product Sales, 2000
    Table 7-5: Leading Suppliers’ Shares of the U.S. Market for OTC Gastrointestinal Products, 2000
    Figure 7-5: Leading Suppliers’ Shares of the U.S. Market for OTC Gastrointestinal Products, 2000

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report